IN THE UNITED STATES BANKRUPTCY COURT
FOR THE DISTRICT OF DELAWARE

In re:	)	Chapter 11
SANGAMO THERAPEUTICS, INC.	)	Case No. 26-10989 (CTG)
Debtor.[1]	)	**Re: Docket Nos. 122, 139, 290 & 346**

NOTICE OF ADDITION TO ACQUIRED CONTRACTS EXHIBIT TO MEROPE SALE ORDER

PLEASE TAKE NOTICE that, on August 20, 2026, the United States Bankruptcy Court for the District of Delaware (the "**Court**") entered the *Order (A) Authorizing and Approving the Debtor's Entry into an Asset Purchase Agreement with Merope Acquisition Sub, LLC (B) Authorizing the Sale of the Acquired Assets Free and Clear of all Claims and Interests, (C) Approving the Assumption and Assignment of the Acquired Contracts, (D) Authorizing the Rejection of Certain Executory Contracts, and (E) Granting Related Relief* [Docket No. 362] (the "**Merope Sale Order**"). The Merope Sale Order, among other things, authorized the above-captioned debtor and debtor-in-possession (the "**Debtor**") to enter into that certain *Asset Purchase Agreement* (the "**Merope Purchase Agreement**") pursuant to which the Debtor agreed to sell (the "**Merope Sale Transaction**") the assets described in the Merope Purchase Agreement to Merope Acquisition Sub, LLC ("**Merope**").

PLEASE TAKE FURTHER NOTICE that, attached to the Merope Sale Order as Exhibit 2 was a list of executory contracts and unexpired leases to be assumed and assigned to Merope in connection with the Merope Sale Transaction (as may be updated from time to time in accordance with the Merope Purchase Agreement and the Merope Sale Order, the "**Acquired Contracts Exhibit**").

PLEASE TAKE FURTHER NOTICE that, pursuant to paragraph 18 of the Merope Sale Order, the Debtor, at the direction of Merope, is authorized to, among other things, add previously omitted executory contracts and unexpired leases as contracts to be assumed and assigned to the Buyer (any such contracts, "**Supplemental Contracts**").

PLEASE TAKE FURTHER NOTICE that Merope has identified the following Supplemental Contract (together with all exhibits, supplements, and amendments thereto) for assumption and assignment in connection with the Merope Sale Transaction.

[1] The Debtor and the last four digits of its taxpayer identification number are: Sangamo Therapeutics, Inc. (9556). The Debtor's mailing address is 501 Canal Blvd., Ste A100, Richmond, CA 94804.

2610989260821000000000005

Supplemental Contract Counterparty	Contract Description	Cure Amount
The General Hospital Corp. (d/b/a Massachusetts General Hospital) 55 Fruit Street Boston, Massachusetts 02144	That certain *Research Agreement*, dated June 1, 2026, as amended	$0.00

PLEASE TAKE FURTHER NOTICE that pursuant to paragraph 19 of the Merope Sale Order, the deadline for the counterparty (the "**Counterparty**") to the Supplemental Contract to file and serve any objection to: (i) the addition of its Supplemental Contract to the Acquired Contracts Exhibit, (ii) the assumption and assignment of its Supplemental Contract to Merope, and (iii) the proposed cure amount set forth above (the "**Cure Cost**") is **August 31, 2026 at 4:00 p.m. (Eastern Time)** (the "**Objection Deadline**").

PLEASE TAKE FURTHER NOTICE that, pursuant to paragraph 20 of the Merope Sale Order, if no objection to this notice is filed and served prior to the Objection Deadline: (a) the Counterparty shall be deemed to have consented to the assumption by the Debtor and assignment to Merope of the Supplemental Contract, and shall be forever barred from asserting any objection with regard to such assumption and assignment; (b) any and all defaults under the Supplemental Contract and any and all pecuniary losses related thereto shall be deemed cured and compensated pursuant to sections 365(b)(1)(A) and (B) of the Bankruptcy Code (i.e. title 11 of the United States Code) upon payment of Cure Costs, if any; (c) the Cure Cost shall be controlling, notwithstanding anything to the contrary in the Supplemental Contract or any other related document; and (d) the Supplemental Contract shall be added to the Acquired Contracts Exhibit, and shall be an Acquired Contract (as defined in the Merope Sale Order).

[*Remainder of Page Intentionally Left Blank*]

Dated: August 21, 2026
Wilmington, Delaware

/s/ Brendan J. Schlauch

Daniel J. DeFranceschi (No. 2732)
Amanda R. Steele (No. 5530)
Brendan J. Schlauch (No. 6115)
RICHARDS, LAYTON & FINGER, P.A.
One Rodney Square
920 N. King Street
Wilmington, Delaware 19801
Telephone: (302) 651-7700
Emails: defranceschi@rlf.com
steele@rlf.com
schlauch@rlf.com
and

Cullen D. Speckhart
Lauren A. Reichardt
Miriam Peguero Medrano
COOLEY LLP
55 Hudson Yards
New York, NY 10001-2157
Telephone: (212) 479-6000
Emails: cspeckhart@cooley.com
lreichardt@cooley.com
mpegueromedrano@cooley.com
and

Robert L. Eisenbach III
COOLEY LLP
3 Embarcadero Center, 20th Floor
San Francisco, CA 94111-4004
Telephone: (415) 693-2000
Email: reisenbach@cooley.com

Counsel for the Debtor and Debtor in Possession